The drs gene was originally isolated as a suppressor against v-src transformation. Expression of drs mRNA was markedly downregulated in a variety of human cancer cell lines and tissues, suggesting that the drs gene acts as a tumor suppressor. In this study, we found that ectopic expression of the Drs protein induced apoptosis in human cancer cell lines. Analyses using deletion mutants of drs revealed that both the C-terminal region and the three consensus repeats in the N-terminal region are essential for the induction of apoptosis. Caspase-12, -9, and -3 were sequentially activated by drs, and specific inhibitors of caspase-3 and -9 suppressed drs-induced apoptosis. The release of cytochrome c from the mitochondria into the cytoplasm was not observed in apoptosis by drs, suggesting that the mitochondrial pathway does not mediate drsinduced apoptosis. Furthermore, we found that the Drs protein can interact with ASY/Nogo-B/RTN-x S , an apoptosis-inducing protein localized in the endoplasmic reticulum, and that coexpression of these genes increased the efficiency of apoptosis. These results indicated that Drs induces apoptosis by a novel pathway mediated by ASY/Nogo-B/RTN-x S , caspase-12, -9, and -3.
Introduction
We previously isolated a novel transformation suppressor gene, drs, against the v-src oncogene (Pan et al., 1996; Inoue et al., 1998) . Although the drs gene is expressed in normal rat fibroblast cells, it is completely downregulated in cells transformed by viral oncogenes such as v-src, v-fps, v-ras, v-mos, v-sis, and v-abl. The drs cDNA has an open reading frame encoding 464 amino-acid residues. This protein has one transmembrane domain, a short intracellular domain in the C-terminus and three consensus repeats (sushi motifs) conserved in the extracellular domain among the selectin family of adhesion molecules and complementbinding proteins (Bevilacqua et al., 1989; Johnston et al., 1989; Reid and Day, 1989; Siegelman et al., 1989; Norman et al., 1991; Lasky, 1992; Kansas, 1996) . We also showed that the expression of drs mRNA is markedly downregulated in a variety of human cancer cell lines and malignant tumor tissues, including those of the colon, bladder, ovary, lung, and prostate (Yamashita et al., 1999; Shimakage et al., 2000; Mukaisho et al., 2002; Shimakage et al., 2002; Kim et al., 2003) . Introduction of drs cDNA by retrovirus vector into these cancer cell lines suppressed anchorage-independent growth without disturbing cell proliferation. The G 1 -S progression of the cell cycle and expression of cyclin A mRNA were suppressed in these cancer cells expressing the drs gene under non-adhesion culture conditions (Yamashita et al., 1999) . These findings suggest that the drs gene is involved in the suppression of malignant transformation in human cancers.
Apoptosis is closely associated with the development of cancer. Alterations of apoptosis-related genes are frequently detected in cancer cells. p53, an apoptosisinducing gene, has been shown to be inactivated in a variety of cancers (Hollstein et al., 1991) . Bcl-2, an antiapoptotic gene, has been found to be overexpressed in B-cell follicular lymphoma and other malignancies (Tsujimoto et al., 1984) . Akt, another anti-apoptotic gene, was first identified as a transforming gene of retroviruses (Bellacosa et al., 1991) . Such alterations by genes involved in apoptosis make cells resistant to apoptosis. The inhibition of apoptosis may be indispensable for the development of cancer. In this study, we investigated the apoptotic activity of the drs gene in human cancer cell lines and found that this gene can cause apoptosis by a novel pathway, including sequential activation of caspase-12, -9, and -3 as well as association with ASY/Nogo-B/RTN-x S , an apoptosisinducing protein, in the endoplasmic reticulum (ER).
Results

Induction of apoptosis by ectopic expression of Drs proteins in human cancer cell lines
To evaluate the apoptotic activity of the drs gene, we constructed expression plasmids that express wild-type (WT) and two deletion mutants, one of which lacks a Cterminal region (CD) and the other of which lacks three sushi motifs (ND) of drs cDNA under the cytomegalovirus (CMV) promoter (Figure 1a) , and we then introduced these plasmids into 293T, a human embryonic kidney cell line, to detect Drs proteins. As shown in Figure 1b , the three plasmids showed similar amounts of Drs proteins 72 h after transfection. However, the ND mutant required only a tenth (0.1 vs 1.0 mg) of the plasmid DNA that the WT or CD mutant required to express a similar amount of Drs protein. Transfection by the expression plasmid of WT caused cell death within 72 h in human cancer cell lines, including HeLa (cervical carcinoma), Saos-2 (osteosarcoma), and T24 (bladder carcinoma), whereas the vector plasmid (vector) scarcely induced cell death (Figure 2a ). The viabilities of these cancer cells transfected with WT were 40-55% 72 h after transfection, whereas those of the cells transfected with vector plasmid were over 90% ( Figure 2b ). To identify the domains of drs responsible for the induction of cell death, we examined the efficiency of cell death by each drs mutant (CD or ND) in HeLa and T24 cells. For both CD and ND, the efficiency of cell death was significantly lower than for WT (Figure 2c ), indicating that both the C-terminal region and the three consensus N-terminal repeats are required for drs to induce cell death.
To clarify whether or not the drs-induced death of these human cancer cells was apoptotic, we performed morphological characterization and fluorescence-activated cell sorting (FACS) analyses of HeLa cells transfected with WT or the vector plasmid (vector). As shown in Figures 3a and b , about 30% of HeLa cells transfected with drs contained morphologically aberrant nuclei with nuclear fragmentation. In HeLa cells transfected with vector plasmid, on the other hand, the population of cells containing aberrant nuclei was below 10%. The population of sub-G 1 fraction characteristics of apoptotic cells was also higher in HeLa cells transfected with WT (Figure 3c ). The population of S phase fraction was not decreased in HeLa cells transfected with WT, suggesting that cell cycle progression is not suppressed by drs. Similar results were These results indicate that an apoptosis pathway is responsible for cell death by the drs gene in human cancer cell lines.
Activation of caspase-3 and -9 by drs without involvement of mitochondria
To clarify the biochemical pathway of drs-induced apoptosis, we investigated the activation of caspases, the key molecules in apoptosis. We initially examined the activation of caspase-3, the effector caspase of apoptosis, by immunoblot analysis of caspase-3 in HeLa cells transfected with drs. The time course experiments showed a marked reduction in the amount of procaspase-3 and increase of cleaved active caspase-3 and cleaved PARP (a substrate of caspase-3) from 48 h after transfection with drs ( Figure 4a ). Transfection with the vector plasmid caused no reduction in procaspase-3 and increase in active caspase-3 and cleaved PARP. Expression of a-tubulin, an internal control, did not change during the time course. The amount of procaspase-3 was also reduced in HeLa cells treated with actinomycin D (Figure 4d, upper panel) . The reduction in procaspase-3 was not induced by the CD mutant or the ND mutant lacking apoptotic activity (Figure 4b ). Experiments using a colorimetrical specific substrate of caspase-3 also showed that WT significantly increased the enzymatic activity of caspase-3, whereas the CD and ND mutants each produced a smaller increase ( Figure 5a ). The increase of enzymatic activity of caspase-3 looks smaller than the cleavage of caspase-3 in immunoblot assay. This may be due to the higher background level of enzymatic assay of caspase-3 activity. To evaluate whether or not caspase-3 must be activated in order for drs to induce apoptosis, we examined the effect of a cell-permeable specific inhibitor of caspase-3 on drs-induced apoptosis in HeLa cells. As a control, we also examined the effect of the inhibitor on apoptosis by actinomycin D, which is known to activate caspase-9 and -3 via a mitochondrial pathway. As shown in Figure 5c (left panel), the inhibitor suppressed drs-induced cell death as well as actinomycin-D-induced cell death in a dose-dependent manner. These results indicate that activation of caspase-3 mediates drsinduced apoptosis.
To clarify the upstream caspase that activates caspase-3 in drs-induced apoptosis, we examined the activation of caspase-8 and -9 by immunoblotting with antibodies for these caspases in HeLa cells transfected with drs. In control experiments, treatment of actinomycin D (Figure 4d , upper panel) increased the amount of active form of caspase-9. It also weakly increased the cleaved intermediates of caspase-8 activation, which is possibly due to a secondary effect within the execution part of the caspase cascade. Treatment of anti-Fas antibody, an inducer of caspase-8-mediated apoptosis by death receptor (Figure 4d , lower panel) activated caspase-8 and -9. The delayed activation of caspase-9 is considered to be due to activation of tBid by caspase-8. Treatment of tunicamycin, an inducer of ER stress coupling cell death (Figure 4e , right panel) activated caspase-9, but did not activate caspase-8. As shown in Figure 4c , the amount of cleaved active form of caspase-9 was significantly increased 36 h after transfection with drs, whereas the amounts of procaspase-8 and intermediates were almost similar during the time course although the amount of intermediates was slightly increased from 72 h after transfection. At 72 h after transfection, the enzymatic activity of caspase-9 was Dose-dependent suppression of drs-induced cell death by cell-permeable caspase inhibitors. The specific inhibitors for caspase-3, -9, and -8 were added to cultures 3 h before supplementation by actinomycin D (ActD, 1 mg/ml) (for caspase-3 and -9, right and left panels) and anti-Fas (0.5 mg/ml) (for caspase-8, middle panel), or just after transfection with WT. The cell viability was quantified by the trypan blue method. Error bars indicate standard deviation A novel apoptotic pathway by drs Y Tambe et al also significantly increased by WT, but was not increased by either the CD or ND mutant (Figure 5b ). The specific inhibitor of caspase-9 also suppressed drsinduced cell death as well as actinomycin-D-induced cell death in a dose-dependent manner (Figure 5c , right panel). However, the specific inhibitor of caspase-8 did not suppress drs-induced apoptosis, although it significantly suppressed anti-Fas-induced cell death (Figure 5c , middle panel). These results indicate that drs-induced apoptosis is mainly mediated by the sequential activation of caspase-9 and -3.
To clarify whether or not drs activates the mitochondria-mediated pathway upstream of caspase-9, we examined the release of cytochrome c from the mitochondria into the cytoplasm in HeLa cells transfected with drs. Although actinomycin D increased the amount of cytochrome c released into the cytoplasm, drs transfection did not increase the release of cytochrome c into the cytoplasm; on the other hand, the COX4 protein, a marker of mitochondria, was detected only in the mitochondrial fraction ( Figure 6 ). These results indicate that the mitochondrial pathway is not involved in drs-induced apoptosis.
Activation of caspase-12 by drs without ER stress
A recent study showed that caspase-9 is activated not only by forming apoptosome in the mitochondriamediated pathway but also by caspase-12, another initiator caspase localized in the ER (Morishima et al., 2002) . To evaluate this possibility, we examined the activation of caspase-12 in HeLa cells transfected with drs. As a positive control, we initially examined the activation of caspase-12 in mouse embryo fibroblast (MEF) cells treated with tunicamycin, an inducer of ERstress coupling cell death, which is known to activate caspase-12. As shown in Figure 4e , the amount of procaspase-12 (42 and 55 kDa bands) was significantly decreased by treatment of tunicamycin. The same bands were detected by the same antibody for caspase-12 and decreased by treatment of tunicamycin in HeLa cells (Figure 4e ), whereas these were hardly affected by treatment of anti-Fas antibody (Figure 4d, lower panel) . Treatment of actinomycin D also reduced the amount of procaspase-12 (Figure 4d, upper panel) . This may reflect a crosstalk between mitochondria-pathway and ERpathway in HeLa cells by actinomycin D (this issue is discussed in the Discussion section). As shown in Figures 4c and f , cleavage of procaspase-12 was observed prior to the activation of caspase-9 (from 12 to 24 h after transfection) in drs-transfected HeLa cells. These results suggest that drs sequentially activates caspase-12, -9, and -3. To investigate the subcellular localization of Drs protein transfection, NIH3T3 cells were transfected with the plasmid expressing the EGFPconjugated Drs. In transfection with WT-EGFP, fluorescence was detected in the perinuclear region (a) and merged with the localization of BiP (b and c), an ER marker protein (Figure 7, upper) . To rule out the possibility that this cell death was caused by an overexpression of unfolded protein in the ER, we examined the localization of EGFP-conjugated mutant Drs proteins of CD or ND, which showed diminished apoptotic activity. As shown in Figure 7 (middle and lower), in cells transfected with CD-EGFP (d) or ND-EGFP (g), fluorescence was detected in the ER at the same intensity as in cells transfected with WT (a) and merged with the localization of BiP (e and f for CD, h and i for ND). This indicated that the mutant Drs proteins cannot induce apoptosis, even though they are localized in the ER. This result also shows that drsinduced apoptosis is not caused by the accumulation of proteins in the ER, but by the physiological function of drs. Furthermore, we examined the expression of BiP, which is induced by ER stress, including that of overexpression of unfolded protein, in HeLa cells transfected by drs. The amount of BiP protein did not change during the time course of transfection by WT (Figure 4c ), although it was markedly increased by treatment of tunicamycin, an inducer of ER stress, in HeLa and MEF cells (Figure 4e ).
Association of Drs with ASY/Nogo-B/RTN-x S in ER
On ER-mediated apoptosis, Li et al. (2001) recently reported that the ASY/Nogo-B/RTN-x S localized in ER has sufficient activity to induce apoptosis. To investigate the correlation between Drs and ASY, we cotransfected the expression plasmids of WT drs and ASY into HeLa cells and compared the efficiency with which the two genes together induced cell death with the efficiency of each individual gene. As shown in Figure 8a , coexpression of Drs and ASY synergistically increased the efficiency of cell death, suggesting that the two proteins interact. To evaluate this interaction, we cotransfected the expression plasmids of WT drs and Flag-tagged ASY into 293T cells, then performed immunoprecipitation and immunoblotting assays using anti-Drs polyclonal antibody and anti-Flag monoclonal antibody. As shown in Figure 8b , the immune complexes precipitated by the anti-Flag antibody contained Drs protein in the cotransfected 293T cells, but not in the singly transfected 293T cells. Conversely, the immune complexes precipitated by the anti-Drs antibody contained Flag-tagged ASY protein (Figure 8b) , indicating the Figure 6 Release of cytochrome c from the mitochondria to the cytoplasm during apoptosis by WT or actinomycin D (ActD). HeLa cells transfected with drs (48 h) or treated with actinomycin D (24 h) were fractionated into the cytoplasm (cyt) and the mitochondria (mit). Immunoblot analyses were performed with a polyclonal antibody for cytochrome c and a monoclonal antibody for COX4, a marker of mitochondria association of Drs and ASY in cotransfected 293T cells. The same experiments were carried out with deletion mutants of drs (CD and ND). Neither of these mutants was co-precipitated with ASY in cotransfected cells (Figure 8c ), indicating that both the C-terminal region and the three sushi motifs are required for the association of Drs with ASY. The association of Drs and deletion mutants of ASY was also examined. A deletion mutant, TTL, which cannot induce apoptosis, was not co-precipitated with EGFP-conjugated Drs in cotransfected cells, while wild-type ASY and a deletion mutant, DBN, which can induce apoptosis were coprecipitated with EGFP-conjugated Drs (Figure 8d ). These results suggest the collaboration of Drs and ASY in ER for the induction of apoptosis.
Discussion
In the present study, we showed that ectopic expression of the drs gene induces apoptosis mediated by sequential activation of caspase-12, -9, and -3 in human cancer cell lines, including HeLa, Saos-2, and T24. In HeLa and Saos-2 cells, the tumor suppressors p53 and Rb are inactivated by the E6 and E7 gene products of human papillomavirus type 18 (HeLa) and by the genetic defect (Saos-2), respectively. p53 has been shown to function as a checkpoint gatekeeper, and it causes either cell cycle arrest in G 1 and G 2 or apoptosis by DNA damage, withdrawal of growth factor, and a variety of stresses in cells (Levine, 1997; Hanahan and Weinberg, 2000; Hollstein et al., 1991) . The main pathway of p53-induced apoptosis involves the efflux of cytochrome c from the mitochondria into the cytoplasm, which results in the activation of caspase-9 and -3 (Shen and White, 2001) . The apoptotic activity of drs in HeLa and Saos-2 shows that the apoptosis pathway induced by drs is either independent of p53 function or downstream of p53. In drs-induced apoptosis; there was no increase in the release of cytochrome c from the mitochondria into the cytoplasm, although caspase-9 and -3 were activated. This supports the idea that drs activates caspase-9 and -3 to induce apoptosis without the involvement of the p53 and mitochondrial pathways. The important which activate caspase-8, another initiator of cysteine protease (Ashkenazi and Dixit, 1998) . However, activation of caspase-8 by drs was significantly lower than anti-Fas-induced cell death and a specific inhibitor of caspase-8 did not suppress drs-induced apoptosis in our experimental conditions, indicating that death ligand/ death receptor-induced apoptotic pathways are not mainly concerned with drs-induced apoptosis. There exists another nonmitochondrial pathway of apoptosis mediated by the ER (Ferri and Kroemer, 2001) . One of the functions of ER is to sense cellular physiological changes. Apoptosis is induced by various ER stresses, including Ca 2 þ depletion and inhibition of both Nglycosylation and protein transport. Caspase-12 has been reported to be localized in the ER, to be activated by ER stresses, and to induce apoptosis (Nakagawa et al., 2000) , although the mechanism by which this caspase is activated is hardly known. Recently, Morishima et al. (2002) reported that caspase-12 activates caspase-9 directly in vitro and mediates ER stress-induced apoptosis in C2C12, a murine myoblast cell line, without involvement of cytochrome c. Although the participation of caspase-12 in human pathologies has been controversial, a protein detectable with diverse anti-murine caspase-12 antibodies is present in humans and this putative human caspase-12 homologue exhibited similar involvement in ER-stressmediated apoptosis (Bitko and Barik, 2001; Rao et al., 2001; Hetz et al., 2003) . We showed that the proteins with a molecular weight of 55 and 42 kDa were recognized by an antibody for mouse caspase-12 in both HeLa and MEF cells, and their amounts were significantly reduced by treatment of tunicamycin, an inducer of ER stress, in both cells (Figure 4e ). We also showed that the amounts of these human procaspase-12 proteins were reduced in HeLa cells transfected by drs. Our results also indicate that drs sequentially activates caspase-12, -9, and -3. The experiments in subcellular localization of Drs in cells transfected with EGFP-conjugated drs indicated that Drs is localized mainly in ER (Figure 7) , although it is also localized in the plasma membrane (data not shown). These results indicate that the ER initiates the drs apoptosis-inducing signals.
ASY was recently isolated as an apoptosis-inducing gene that encodes an ER-targeting protein and is downregulated in small cell lung cancer (Li et al., 2001) . We found that Drs can interact with ASY and synergistically enhance apoptosis with ASY. ASY is identical to the Nogo-B, a splice variant of the Nogo-A; the latter has been shown to inhibit neuronal regeneration in the central nervous system (Chen et al., 2000) . ASY is also identical to the RTN-x S , which was shown to interact with both Bcl-x 1 and Bcl-2 on ER and to reduce their anti-apoptotic activity (Tagami et al., 2000) . These findings suggest that Drs induces apoptosis in association with apoptosis-regulating proteins in ER. Recent studies showed that proapoptotic and antiapoptotic Bcl-2 family proteins, including Bcl-2, Bcl-x L , Bax, and Bak, could be localized on ER as well as mitochondria, and could regulate apoptosis induced by ER stress or alterations in Ca 2 þ homeostasis (Hacki et al., 2000; Annis et al., 2001; Rudner et al., 2001; Scorrano et al., 2003) . These findings suggest a crosstalk between the mitochondria and ER pathways of apoptosis. Activation of caspase-12 as well as caspase-9 in actinomycin-D-treated HeLa cells (Figure 4d , upper panel) may reflect this crosstalk. Although we also examined the association of Drs with Bcl-x L or Bcl-2 by coexpression experiments in 293T, no interaction was detected between Drs and any of these anti-apoptotic proteins under our experimental conditions (data not shown). Further studies on the association of Drs with other Bcl-2 family proteins will be needed to clarify the mechanism of activation of caspase-12 by Drs/ASY complexes.
As Oertle et al. (2003) recently pointed out, overexpression of a foreign protein by transfection in the ER often induces apoptosis. Our experiments using deletion mutants of drs ruled out this possibility. Induction of apoptosis by drs is not a nonspecific stress response, but a physiological function of the drs gene. This apoptosisinducing function of drs depended on the C-terminal region and three sushi motifs. We previously reported that retrovirus-mediated stable expression of drs suppresses anchorage-independent growth of human cancer cell lines, and that regions lacking in CD and ND mutants are necessary for this activity (Yamashita et al., 1999) . This suggests, in conjunction with the results of the present study, the importance of these regions for tumor suppression through drs. To understand the function of drs fully, it will be necessary to clarify the roles of the C-terminal region and the three sushi motifs of the N-terminal.
The involvement of drs in ER-mediated apoptosis proposes a possible tumor-suppression mechanism for this gene. Our findings suggest the existence of a novel ER-mediated pathway for apoptosis, one that is different from the known mitochondrial pathway involving p53, Bcl-2, and Akt to suppress tumor development. Elucidation of an ER-mediated pathway of drs-induced apoptosis will provide new insights into the mechanisms of apoptosis in cancer cells.
Materials and methods
Cell lines
The cell lines used in this study were 293T (a human embryonic kidney cell line expressing the E1 gene of adenovirus type 5 and the T antigen of SV40), NIH3T3 (a mouse fibroblast cell line), HeLa (a human cervical carcinoma cell line), T24 (a human bladder carcinoma cell line), and Saos-2 (a human osteosarcoma cell line). All cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS).
Plasmids and transfection
The expression plasmids of the wild type (WT) and the mutant drs (CD and ND) were constructed as follows. A drs mutant lacking a 57-bp C-terminal region (CD) was amplified with the oligoprimer 5 0 -UTR of drs and with its 3 0 -primer. A drs mutant lacking a 792-bp N-terminal region of three consensus repeats (ND) was constructed by AluI and PvuII digestion and ligation. All series of drs cDNA were cloned into a pCR3.1 vector containing CMV promoter and the neo-resistant gene (Invitrogen). The expression plasmids of EGFP-conjugated drs were constructed by in-frame insertion of the wild type or mutants of drs into pCX-EGFP, an EGFP expression plasmid (Okabe et al., 1997) . The plasmid pCFASY, for the expression of Flag-tagged ASY, and the plasmids of Flag-tagged TTL and DBN mutants of ASY were previously described (Li et al., 2001) . All recombinant plasmids were prepared using Qiagen columns (Qiagen). Transfection was carried out using Lipofectaminet PLUS Reagent (Invitrogen) according to the manufacturer's protocol.
Antibodies
Rabbit polyclonal antibody for Drs was obtained from rabbits immunized with thioredoxin-fused recombinant rat Drs protein expressed in Escherichia coli. Rabbit polyclonal antibody for ASY was obtained from rabbits immunized with recombinant human ASY protein expressed in E. coli. Anticaspase-3 (H277, polyclonal) antibody was purchased from Santa Cruz Biotechnology. Antibody for cleaved caspase-3 (Ab-4, monoclonal) was purchased from Oncogene Research Products. Antibody for caspase-8 (12F5, monoclonal) was purchased from Alexis. Anti-caspase-9 (5B4, monoclonal), anti-caspase-12 (BV-3182-3, polyclonal), anti-Fas (CH11, monoclonal), and anti-cleaved-PARP (BV-3140-3, polyclonal) antibodies were purchased from MBL. Anti-a-tubulin (DM1A, monoclonal) and anti-Flag (M2, monoclonal) antibodies were purchased from Sigma. Anti-BiP monoclonal (clone 40) and polyclonal (SPA-826) antibodies were purchased from BD Transduction Laboratories and Stressgen Biotechnologies, respectively.
Apoptosis assays
Cell death was determined quantitatively by the trypan blue staining method. For the morphological characterization of apoptosis, cells were stained with 10 mM Hoechst 33342, and the nuclei were examined for morphological change under a fluorescence microscope. The quantification of the sub-G 1 fraction was examined by FACS analysis. The cells were fixed with 70% ethanol at 41C for 20 min. After washing with PBS(À), the cells were incubated with 10 mg/ml RNaseI at 371C for 20 min, stained with propidium iodide, and analysed for DNA content by using FACScan (Becton Dickinson). The enzymatic activities of caspase-3 and -9 were examined using a colorimetric protease assay kit (MBL) according to the manufacturer's protocols. The inhibitor assays of caspase-3, -8, and -9 were performed by supplementing the cell-permeable caspase-3 inhibitor I, caspase-8 inhibitor I, and caspase-9 inhibitor II (Calbiochem) just after transfection with drs. The release of cytochrome c from the mitochondria to the cytoplasm was detected by immunoblotting with rabbit polyclonal antibody for cytochrome c after subcellular fractionation using the ApoAlert cell fractionation kit (Clontech) according to the manufacturer's protocol.
Immunoblotting
The cells were lysed in Laemli-SDS buffer containing 62.5 mM Tris-HCl (pH6.8), 10% glycerol, 5% 2-mercaptoethanol, 2% sodium dodecyl sulfate (SDS), 0.01% bromophenol blue, 5 mM EDTA, and 1 mM orthovanadate. A sample of cell lysate was subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and the separated proteins were electrotransferred onto membrane filters (Immobilon-P, Millipore). After blocking with TBS-T (10 mM Tris-HCl, pH7.6, 150 mM sodium chloride, 0.1% Tween 20) containing 5% bovine serum albumin (BSA), the filters were incubated with an antibody described above in TBS-T containing 2% BSA for up to 5 h. The filters were then washed in TBS-T and incubated for 1 h in horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG (Amersham International) diluted 1 : 20 000 in TBS-T containing 2% BSA. After several washes with TBS-T, the immunoreactivity was detected by the ECL system (Amersham International) using the procedures recommended by the manufacturer.
Immunofluorescence staining
The cells were fixed with 4% paraformaldehyde for 10 min, permeabilized with 0.1% Triton X-100 for 5 min, and incubated successively with a primary polyclonal antibody for 1 h and with a secondary fluorescence-labeled anti-rabbit IgG for 30 min.
Immunoprecipitation
The cells were lysed in RIPA buffer containing 20 mM TrisHCl (pH7.4), 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, and 1% protease inhibitor cocktail (Nacalai Tesque), and was centrifuged for 30 min in 10 000 g at 41C. The supernatant was incubated with primary antibody at 41C for 1 h. The immunocomplexes were bound to protein-G sepharose for 1 h at 41C and washed three times with RIPA buffer. The proteins bound to the protein-G sepharose were eluted by adding Laemli-SDS sample buffer and boiling for 2 min. After centrifugation at 10 000 g for 2 min, the supernatant was analysed by immunoblotting.
